), upgrading IRBT from Neutral to Overweight. In a note to clients, J.P. Morgan writes, "We are upgrading IRBT to Overweight from Neutral on valuation. There is no change to our estimates nor our December 2011 price target of $38.00. Exiting last week's analyst day event and the J.P. Morgan TMT conference session, we are confident that IRBT remains on track for 20% CAGR EBITDA growth through 2014 on revenue growth of about 15%, with potential for upside if the US Army's adoption of SUGVs accelerates. The stock has pulled back 19% from an all-time high of $38.42 on April 26, which is an attractive entry point in our view." Shares of IRBT closed Friday at $31.22, up 1.89% from Thursday's close.